Editorial board member Mario Cazzola (University of Rome Tor Vergata, Rome, Italy) discusses the background and findings of his late-breaking presentation entitled: Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis.
1. Why was there a need for the meta analysis of inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) and LABA/long-acting muscarinic antagonist (LAMA) fixed dose combinations on lung function and exacerbation of chronic obstructive pulmonary disease (COPD)? (0:12)
2. What were the findings of this analysis? (0:49)
3. Which of the LAMA/LABA combinations were found to be the most effective? (1:37)
4. What (if any) were the limitations of this study? (2:27)
5. Which emerging LAMA/LABA combinations require further study? (3:22)
Speaker disclosure: Mario Cazzola has participated as a speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, Novartis, Pfizer, Verona Pharma, and Zambon, and is or has been a consultant to Chiesi Farmaceutici, Lallemand, Novartis, Verona Pharma, and Zambon.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In COPD
Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial
It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing inhaled […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!